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PURPOSE. To analyze the activity of mitogen-activated protein kinase (MAPK) and
phosphoinositide 3-kinases/mechanistic target of rapamycin (PI3K/mTOR) pathways in
benign and malignant conjunctival melanocytic proliferations and explore whether specific
inhibitors can suppress growth of conjunctival melanoma (CJM) cells.
METHODS. The presence of a BRAF V600E mutation and activation of ERK, MEK, S6, and AKT
were assessed with immunohistochemistry in 35 conjunctival nevi and 31 melanomas. Three
CJM cell lines were used: CRMM1, carrying the BRAF V600E mutation; CRMM2, harboring
the NRAS Q61L mutation; and T1527A, with a BRAF G466E mutation. WST-1 assays were
performed with a BRAF inhibitor (vemurafenib), two MEK inhibitors (trametinib,
selumetinib), a PI3K inhibitor (pictilisib), and a dual PI3K/mTOR inhibitor (dactolisib). The
phosphorylation of ERK, MEK, and S6 were tested with western blots and apoptosis with
cleaved caspase-3 immunostaining.
RESULTS. A BRAF V600E mutation was detected in 42.6% of nevi and in 35.5% of CJM. MEK and
ERK activation were higher in CJM, occurring in 62.9% and 45.7% of the nevi and 90.3% and
96.8% of the CJM, respectively. There was also a significant increase in S6 activation in CJM
(90.3%) compared with the nevi (20%). CRMM1 was sensitive to trametinib and the PI3K
inhibitors but only marginally to vemurafenib. CRMM2 was moderately sensitive to pictilisib,
whereas T1527A was resistant to all drugs tested.
CONCLUSIONS. The MAPK pathway activity in CJM is increased, not only as a consequence of
the BRAF V600E mutation. Targeted therapy may be useful for patients with CJM, especially
those with activating BRAF mutations, whereas NRAS-mutated melanomas are relatively
resistant.
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Conjunctival melanoma, whose incidence increased from1990 to 1999 in the United States (0.46/million),1 is
associated with a high recurrences rate, ranging from 32% to
62%.2,3 The therapeutic management of metastatic conjunctival
melanoma is challenging and metastatic death occurs in 9% to
35% of patients at 10 years postdiagnosis.4–6
Conjunctival and cutaneous melanomas not only share
common clinical features, such as metastatic spread through
the lymphatic system, but also share some molecular features.
The mutation spectrum appears to be similar to cutaneous
melanoma, with a majority of cytosine to thymine transitions
(C>T)7,8 suggesting a high impact of UV light-induced damage.
The high mutation load with ~90,000 mutations in the entire
genome7 is also similar to skin melanoma9 and contrasts sharply
with the low mutation load identified in uveal melanoma.10
Mutations commonly observed in cutaneous melanoma, such as
V600E in exon 15 of BRAF or Q61L in exon 3 of NRAS8,11 are
also identified in conjunctival melanoma, with BRAF mutations
being found in 29% to 35%12,13 and NRAS mutations in 18% of
the cases.12 More recently, NF1 mutations could be identified in
33% of the patients.14
Numerous studies have assessed the importance of the
mitogen-activated protein kinase (MAPK) pathway in cutaneous
melanoma.15 Small-molecule inhibitors, binding to the active
conformation of BRAF and blocking access to ATP, disrupt
MAPK signaling, reduce proliferation in vitro, and induce tumor
regression in vivo in BRAFV600E melanomas.16,17 In patients
with metastatic melanoma carrying the BRAFV600E mutation,
these inhibitors were associated with an impressive complete
or partial tumor response.18–20
Direct MEK targeting downstream of BRAF represents an
alternative way to overcome tumor resistance in patients with
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BRAF-mutated skin melanomas. Trametinib, an allosteric and
highly selective MEK inhibitor, significantly improved progres-
sion-free survival and overall survival in patients with BRAF
mutant metastatic melanoma.21
NRAS mutations, usually mutually exclusive with BRAF
mutations, occur in 20% to 30% of skin melanomas and more
commonly in older patients.11,22 The RASQ61L mutation impairs
hydrolysis of guanosine-50-triphosphate (GTP) to guanosine
diphosphate (GDP) and the transition of NRAS from an active
to an inactive state. Downstream single inhibition of the MAPK
pathway through MEK inhibition,22 alone or in combination
with phosphoinositide 3-kinases/mechanistic target of rapamy-
cin (PI3K/mTOR) inhibition,23 has been attempted in NRAS-
mutated melanoma. Although in vitro MEK inhibitors appeared
more successful than PI3K inhibitors, the combined use of
MEK and PI3K reduced cell viability and tumor size in vivo
models more efficiently.24
The efficiency of direct BRAF inhibition in conjunctival
melanoma (CJM) has been evaluated in vitro in two stud-
ies.25,26 The response to BRAF inhibition in advanced
metastatic CJM has been variable, ranging from a partial
response lasting 1 month27 to significant tumor regression
peaking after 4.5 months.28 A complete regression for 38
months of an irradiated metastatic CJM treated with vemur-
afenib has also been documented.29
We conducted a study to assess the activity of the MAPK
and PI3K/mTOR pathways in conjunctival melanomas tissues
in relation to the presence or absence of the oncogenic
BRAFV600E mutation. We also assessed in vitro the response of
conjunctival melanoma cell lines containing defined BRAF and
NRAS mutations to BRAF, MEK, PI3K, and dual PI3K/mTOR
inhibitors.
MATERIALS AND METHODS
Patients
The clinical charts of patients treated for conjunctival
melanoma or conjunctival nevi in Jules-Gonin Eye Hospital
from 1998 until 2013 where formalin-fixed paraffin-embedded
tissue was available were selected. The following clinical
information was retrieved from the patients’ charts: age, sex,
tumor localization, treatment, recurrences, metastases, death,
and length of follow-up. The study was approved by the Swiss
Federal Department of Health (authorization 032.0003-48) as
well as local ethic committee (protocol 340/15) and adhered to
the tenets of the Declaration of Helsinki.
Tissues
Formalin-fixed paraffin-embedded tissues were retrieved from
the archives of Jules-Gonin Eye Hospital Pathology Laboratory.
Sections (5 lm) were cut, and hematoxylin-eosin stains were
performed. The sections were incubated with the following
anti-human antibodies: anti-phospho-MEK (Ser221, rabbit
monoclonal; Cell Signaling, Danvers, MA, USA; dilution
1:200), anti-phospho-ERK (Thr202 /Tyr204, rabbit monoclonal;
Cell Signaling; dilution 1:600), anti-phospho-AKT (Ser473,
rabbit monoclonal, dilution 1:50), and anti-phospho-S6
(Ser235/236, rabbit monoclonal; Cell Signaling; dilution
1:200). Positive controls were found in endothelial cells of
conjunctival stroma and conjunctival epithelium for anti-
phospho-S6, anti-phospho MEK, and ERK (Supplementary
Fig. S1). For phospho-AKT, a phospho-AKT (Ser 473) slide
with LNCaP cells treated with or without a PI3K inhibitor,
LY294002, was used. A streptavidin/biotin detection method
with 3,30-diaminobenzidine tetrachloride or 3-amino 9-ethyl-
carbazole was used for signal detection (Dako Envision System/
HRP Dual Link; Dako Agilent, Santa Clara, CA, USA).
The BRAF V600E mutation was assessed in the tissues using
a BRAFV600E-specific monoclonal antibody (clone VE1, mouse
monoclonal; Ventana Medical Systems, Oro Valley, AZ, USA)
with a BenchMark Ultra platform (Roche Diagnostics, Rot-
kreuz, Switzerland).
The proportion of positively stained cells was scored in the
following manner: 0% to 10% positive cells: score 1; >10% to
50%: score 2; and >50% to 100%: score 3. Three independent
observers (APM, MB, and MN) evaluated the immunostained
slides and discordant cases were reviewed simultaneously to
reach a concordant agreement.
There was a concordance of 75.8%, 88.6%, 95,4%, 93.9%,
and 93.9% among the observers and the evaluation of pMEK,
pERK, cytoplamic pAKT, nuclear pAKT, and pS6, respectively.
Cells
Conjunctival melanoma cell lines CRMM1 and CRMM2,
established by Gordon Nareyeck, University of Essen, Germany,
were kindly provided by Martine Jager, University of Leiden
with the authorization of use granted from Gordon Nareyeck.
The cells were cultured in F-12K nutrient mixture, with
Kaighn’s modification, containing L-glutamine (Gibco, Life
Technologies, Carlsbad, CA, USA), 10% heat-inactivated fetal
bovine serum (Greiner Bio-one, Kremsmuenster, Austria) and
2% penicillin/streptomycin (Gibco). T1527A was established in
our laboratories (Jules-Gonin Eye Hospital and Ludwig Center
for Cancer Research, Switzerland) from a perilimbic conjunc-
tival melanoma extending onto the cornea in a 65-year-old
man. These cells were grown in a mixture of 50% of RPMI 1640
modified media (Gibco) and 50% Dulbecco’s modified Eagle’s
medium (DMEM) F-12 (nutrient mixture with GlutaMAX;
Gibco) supplemented with 10% fetal bovine serum (Greiner
Bio-one) and 6 mM N-2-hydroxyethyl-1-piperazine-N0-2-ethane-
sulfonic acid (HEPES; Gibco). An analysis of the full length of
BRAF in the original tumor and the derived cell line T1527A
revealed the mutation G466E in exon 11 of BRAF in both
samples (Supplementary Fig. S2). NRAS was found to be wild
type in both the cell line and the original tumor. In addition,
next-generation sequencing of the tumor, performed as in
Rivolta et al.,7 did not reveal any mutation in NF1. An analysis
of HRAS revealed the heterozygous mutation Q61R in the
T1527A cell line.
Reagents
Vemurafenib (PLX4032, S1267), pictilisib (GDC-0941, S1065),
selumetinib (AZD6244, S1008), trametinib (GSK1120212,
S2673), and dactolisib (BEZ 235) were purchased from Selleck
Chemicals (Huissen, The Netherlands). All drugs were dis-
solved in dimethyl sulfoxide (DMSO) to reach a stock
concentration of 10 mM.
WST-1 Assay
The WST-1 assay, a colorimetric test that was developed to
determine the survival and growth of eukaryotic cells in
proliferation or to evaluate cytotoxicity,30 was used to evaluate
cell viability and calculate the half maximal inhibitory
concentration (IC50) of the drugs.
Briefly, cells were seeded in a 96-multiwell plate at a density
of 5000 to 6000 cells/well in 200 ll of medium. The following
day, cells were treated with increasing concentrations of kinase
inhibitors. Twenty four and 72 hours later, Cell Proliferation
Reagent WST-1 (20 ll) was added to each well,31 including the
wells that contained only medium (with corresponding diluted
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DMSO). Plates were then incubated for 1 hour at 378C in the
dark and analyzed with a microplate reader (Hidex Sense;
Hidex, Turku, Finland) at 420 nm versus 650 nm. Experiments
were performed in triplicate and repeated three times. IC50
values were calculated using GraphPad software (GraphPad
Software, San Diego, CA, USA).
Western Blot Analysis
Cells were disrupted in radioimmunoprecipitation assay buffer
(50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, and 1% sodiumdodecyl sulfate) in the presence
of protease and phosphatase inhibitors. Protein concentration
was measured using a Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific, Waltham, MA, USA).32
Proteins were boiled in Laemmli buffer (62 mM Tris-HCl
[6.8 pH], 2% SDS, 10% glycerol, 5% b-mercapto-ethanol, and
0.01% bromophenol blue). After blocking with 5% BSA in PBS
for 1 hour at room temperature, membranes were incubated
overnight at 48C with the following primary antibodies: anti-
ERK and anti-phospho-ERK (Cell Signaling; catalog no. 4695
and catalog no. 4370S, used at 1:1000); anti-MEK and anti-
phospho-MEK (Cell Signaling; catalog no. 9126S and catalog
no. 2338S, 1:1000); anti-S6 ribosomal protein and anti-
phospho-S6 ribosomal protein (Cell Signaling; catalog no.
2217S and catalog no. 4858 S, 1:1000); and anti-alpha-tubulin
(Sigma; catalog no. T5168, 1:4000). Horseradish peroxidase-
conjugated anti-rabbit (Dako; P0399) or anti-mouse (Dako;
P0447) antibodies, diluted 1:5000, were used as secondary
reagents. Visualization of the immunoreactive bands was
obtained by a chemoluminescent substrate, Super Signal West
Pico Chemiluminescent Substrate (Thermo Fischer Scientific,
Waltham, MA, USA) using fusion solo chemiluminescence and
optional fluorescence imaging system.
Indirect Immunofluorescence Experiments
Cells were seeded at a density of 10/well in 1 ml of complete
medium in Lab-Tek devices (4 wells, glass slide; Thermo Fisher
Scientific). Cells were treated with various kinase inhibitors at
their respective IC50 concentrations. The activation of caspase-
3 was evaluated 24 hours later by immunofluorescence with
cleaved caspase-3 (catalog no. AP3725a; Abgent, San Diego,
CA, USA; dilution 1:100, overnight incubation at 4 C8;
secondary antibody [Invitrogen, Carlsbad, CA, USA]; A11037;
Alexa Fluor; dilution 1:300). Cells were observed using a
fluorescence microscope, Olympus BX51 (Olympus, Shinjuku,
Tokyo, Japan), equipped with 403 and 603 objectives.
Statistical Analysis
Statistical analysis was performed using JMP 8.0 software (SAS,
Cary, NC, United States), GraphPad Prism 5 program (Graph-
Pad Software) and R statistical software, version 3.5.1 (R
Foundation for Statistical Computing, Vienna, Austria).
Tests of significance were two-tailed, and results were
considered as significant at an alpha level of P < 0.05, and a P
value of 0.05 was considered to be borderline significant.
Fisher’s exact tests were used to establish an association
between two qualitative variables. Mann-Whitney U test was
used to compare continuous variables.
RESULTS
Clinicopathologic Characteristics
The nevi group (n ¼ 35) comprised 13 subepithelial and 22
compound nevi. The male/female patient ratio was 21/14, with
a mean age of 36.9 (SD, 21.3 years). None of the nevi occurred
in the tarsal conjunctiva and nine nevi arose in the caruncula.
None of the nevi recurred (mean follow up, 31.5 months [SD,
29.9 months]).
The melanoma group (n¼ 31) consisted of 15 males and 16
females, with a mean age of 66.25 (SD, 20.4 years). According
to the last American Joint Committee on Cancer TNM
classification, 12 tumors belonged to the T1, 7 to the T2, and
12 to the T3 category. Melanomas arose mostly from primary
acquired melanosis (67.8%) and less frequently from a nevus
(19.3%) or de novo (12.9%). The origin of melanoma was
determined by a combination of clinical and histopathologic
factors.
Mean follow-up was 55 months (SD, 76.3 months). Local
recurrences were found in 58.6% of the cases. Metastases
developed in 10 patients, of whom 4 died.
Pathway Activation in the Tissues
The BRAF mutation was detected with immunohistochemistry
in 42.6% (15/35) of the nevi and 35.5% (11/31) of the
melanomas. In the nevi, BRAF mutation was more frequent in
the subepithelial nevi (69%, 9/13) than in the compound nevi
(27%, 6/22; Fisher P ¼ 0.032). In the melanomas, BRAF
mutation was not significantly correlated with any clinicopath-
ologic factor (sex, age, tumor localization, melanoma origin
[nevus, primary acquired melanosis, de novo], depth of
invasion, proliferative activity, local lymphatic invasion, local
recurrence, and metastases; Supplementary Table S1), but our
study included only 31 melanomas.
Activation of the MAPK and AKT pathways in nevi and
conjunctival melanomas was assessed by immunohistochemis-
try using antibodies specific for the phosphorylated forms of
MEK, ERK, AKT, and S6 proteins, as detailed in the Materials
and Methods section. The results are summarized in Table 1
and Figure 1 (nevi) and Figure 2 (melanomas), as well as
Supplementary Table S1. Considering as positive those lesions
containing at least 10% stained melanocytic cells (i.e., those
TABLE 1. MAPK and pi3K Pathway Activation in Conjunctival Nevi and
Melanomas
Protein
n (%)
P Value*Nevus, n ¼ 35 Melanoma, n ¼ 31
pMEK 0.0008
Score 1 13 (37) 3 (10)
Score 2 14 (40) 9 (29)
Score 3 8 (23) 19 (61)
pERK <0.0001
Score 1 19 (54) 1(3)
Score 2 11 (31) 12 (39)
Score 3 5 (14) 18 (58)
pAKTc 0.002
Score 1 2 (6) 0
Score 2 18 (51) 6 (32)
Score 3 15 (43) 25 (68)
pAKTn 0.316
Score 1 2 (6) 1 (3)
Score 2 9 (26) 14 (45)
Score 3 24 (69) 16 (52)
pS6 <0.0001
Score 1 28 (80) 3 (10)
Score 2 7 (20) 18 (58)
Score 3 0 10 (32)
Significant P values < 0.05 are highlighted in bold.
* Cochran-Armitage test.
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scored as 2 and 3 in our scoring method), cytoplasmic MEK
activation was found in 62.9% of the nevi and in 90.3% of the
melanomas (Cochran-Armitage test, P ¼ 0.0008). ERK phos-
phorylation was detected both in the nucleus and the
cytoplasm in 45.7% of the nevi and in 96.8% of the melanoma
cases (Cochran-Armitage test, P < 0.0001). There was good
correlation between the activation of ERK in the cytoplasm
and nucleus (Cochran-Armitage test, P < 0.0001).
Cytoplasmic pAKT was positive (score 2 or 3) in 94.3% of
the nevi and in all melanomas, and similarly, nuclear pAKT was
FIGURE 1. Activation status of the MAPK and PI3K pathways in a conjunctival subepithelial nevus. A BRAF V600E mutation can be identified with
immunohistochemistry (D). There is no significant activation of MEK (B) or ERK (E) or S6 (F), as indicated by immunostaining with antibodies to
the respective phosphoproteins. AKT (C) activation can be observed in some cells. (A) Corresponding area demonstrating a subepithelial nevus
with pseudoglands containing goblet cells (stain: hematoxylin-eosin). (B) phospho-MEK. (C) phospho-AKT. (D) BRAFV600E. (E) phopho-ERK. (F)
phospho-S6. (A–F) Magnification: 3126; insets (B–F): magnification: 3252.
FIGURE 2. MAPK and PI3K pathways in an advanced conjunctival melanoma. Despite the absence of the BRAF V600E mutation (D), there is an
activation of MEK (B) and ERK translocating to the nucleus (E) as well as an activation of AKT (C) and S6 (F). (A) Corresponding area with sheets of
pleomorphic, atypical melanoma cells (stain: hematoxylin-eosin). (B) phospho-MEK. (C) phospho-AKT. (D) BRAFV600E. (E) phopho-ERK. (F)
phospho-S6. (A–F) Magnification: 3126; inlets (B–F) magnification: 3252.
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identified in 94.3% of the nevi and in 96.8% of the melanomas.
However, the proportion of CJM samples with a more
extensive staining (score 3) was higher (80.6%) than observed
in nevi (42.9%; Cochran-Armitage test, P ¼ 0.002). PS6 was
found in 20% of nevi and in 90.3% of melanoma (Cochran-
Armitage test, P < 0.0001).
A significant correlation was found between the activation
of MEK and ERK in both melanomas and nevi (Fisher, P ¼
0.022). There was no correlation between the activation of
AKT and the downstream activation of S6.
There was no correlation between the presence of BRAF
mutation detected with immunohistochemistry and the
activation of MEK, ERK, AKT, and S6.
In the melanomas, there was no correlation between the
activation of AKT, S6, MEK, or ERK and the TNM stage, depth
of invasion, proliferative activity, local lymphatic invasion or
local recurrences, metastases, and death (Supplementary Table
S1).
In Vitro Responses to MAPK and AKT Inhibitors
To evaluate the sensitivity of conjunctival melanoma cells to
inhibitors targeting the signaling pathways implicated in
tumorigenesis, cultured conjunctival melanoma cell lines
containing characterized BRAF and NRAS mutations were
treated with different concentrations of vemurafenib (BRAF
inhibitor), selumetinib and trametinib (MEK inhibitors),
pictilisib (AKT inhibitor), and dactolisib (a dual PI3K/mTOR
inhibitor). The effect on viability was measured after 24 and 72
hours of treatment using the WST-1 assay (Fig. 3; Supplemen-
tary Fig. S3). Figure 3 shows that the cell lines had different
sensitivity to the drugs. IC50 values calculated for the inhibitors
are summarized in Table 2. CRMM1 was the only cell line
sensitive to inhibitors of both MAPK (vemurafenib and
trametinib) and AKT (pictilisib and dactolisib) pathways.
However, sensitivity to vemurafenib was weak (just above 1
lM), despite the presence of BRAFV600E mutation. CRMM2 was
moderately sensitive to pictilisib, whereas T1527A was
resistant to all inhibitors tested. Our analysis revealed that
T1527A was harboring not only a BRAFG466E mutation but also
a HRASQ61R mutation. The HRASQ61R mutation was possibly
already present at a lower level in the primary tumor (CM3-T)
from which it was derived (Supplementary Fig. S2).
To assess the involvement of apoptosis in the drug-induced
effect on viability, we asked whether the caspase-3 apoptosis
pathway was activated in the more sensitive CRMM1 cells
treated with the various inhibitors at IC50 concentrations.
Immunocytochemistry of cleaved caspase-3 showed cells with
increased perinuclear staining following a 24-hour treatment
with the inhibitors but not in CRMM1 cells without the
inhibitors (Supplementary Fig. S5).
FIGURE 3. Dose-dependent effect of different MAPK and PI3K/mTOR pathway inhibitors on the growth of CJM cells (CRMM1, CRMM2, and
T1527A). Cells were treated with the indicated inhibitors at the indicated concentrations for 72 hours. Cell viability was evaluated using the WST-1
assay. Values show mean 6 SD of triplicate measurements. These are representative results of three different experiments.
TABLE 2. IC50 Values of Inhibitors in Conjunctival Melanomas
Cell Line Vemurafenib (lM) Selumetinib (lM) Trametinib (nM) Pictilisib (nM) Dactolisib (nM)
CRMM1 1.08 7 9.8 10 14
CRMM2 >10 10 360 500 1700
T1527A >100 >10 >10,000 >10 >10,000
IC50 values were calculated from viability assays (as shown in Fig. 3) performed on cells treated with the indicated inhibitors for 72 hours. Values
are the mean of three independent experiments. IC50 values demonstrate that CRMM1 is at least partially sensitive to vemurafenib, trametinib,
pictilisib, and dactolisib. CRMM2 is only sensitive to pictilisib and trametinib, whereas T1527a is not sensitive to any of the drugs tested.
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Effect of Kinase Inhibitors on Phospho-MEK, -ERK,
and -S6 Levels
To understand the different sensitivity of the cell lines tested to
the inhibitors, Western blot analyses were first performed to
assess the basal levels of phosphorylated (activated) and total
ERK, MEK, and S6 proteins in CJM cell lines. All three cell lines
displayed a constitutive activation of the above proteins
(Supplementary Fig. S4).
To assess whether the responses to inhibitors were
pathway-specific, we treated the cell lines harboring activating
BRAF and NRAS mutations, that is CRMM1 and CRMM2, with
MEKi (trametinib and selumetinib) or dual PI3K-mTORi
(dactolisib) for 24 hours and assessed the effects on the
activation of MEK, ERK, and S6 with Western blotting. In
CRMM1 and CRMM2 (Fig. 4A), the lowest dosage of
selumetinib (0.1 lM) greatly inhibited the phosphorylation of
both MEK and downstream ERK. Trametinib caused similar
concentration-dependent decreases in the phosphorylation of
MEK and ERK in the two cell lines. In both cases, levels of total
MEK and ERK remained unchanged (Fig. 4B). Phosphorylation
of S6 was inhibited by dactolisib in both cell lines (Fig. 4C).
Altogether, the drugs showed activity on relevant targets in
both cell lines.
DISCUSSION
As a significant proportion of conjunctival melanomas contains
BRAF or NRAS mutations, we directly tested in the tumor
tissues the activation of the downstream pathways, that is the
MAPK and PI3k/mTOR pathways. The BRAFV600E mutation was
found in 42.6% of the nevi and 35.5% of melanomas. The
presence of this BRAF mutation in conjunctival nevi has been
documented in 19%25 to 50%33 of cases, a lower rate than in
cutaneous nevi, where BRAFV600E has been identified in 60%34
to 87.5%.35–37 Based upon this study and previous reports, a
BRAFV600E mutation occurs in 26%25 to 35%13,28 of conjunc-
tival melanomas. Although a BRAFV600E occurred at an earlier
age in our study with respect to what has been previously
reported in Denmark13 (62.09 years versus 68.55 years), this
was not significant.
Our results demonstrate that the MAPK pathway is
constitutively activated in both conjunctival nevi and melano-
mas. Moreover, the fact that a BRAFV600E mutation is less
frequent in melanomas than in nevi implies that the increased
activation of this pathway identified in our study may not
depend only upon a BRAF oncogenic mutation. It is
understood that the modulation of the MAPK pathway results
from a fine balance between positive and negative regulators.
Apart from BRAFV600E, the loss of the negative control by NF1
may partially explain this enhanced MAPK activity. In
cutaneous melanoma, an NF1 mutation is an important event,
identified within 14% of cases by the tumor genome atlas
project.11 Recently, NF1 mutations could be identified in 21 of
63 conjunctival melanomas (33%).14 Alternatively, the in-
creased MAPK activity may also be directly explained by the
presence of other oncogenic mutations, such as NRAS
mutations, discovered in 18% of conjunctival melanoma
cases.28 By analogy, in 32 NRAS-mutated cutaneous melano-
mas, increased activity of the MAPK pathway was observed in
more than 60% of cases.24
In the conjunctival melanomas, we encountered an almost
significantly increased nuclear localization of AKT compared
with the nevi, as well as a concomitant increased phosphor-
ylation of S6, suggesting an increased activity of the Pi3k/
mTOR pathway, which could be partially explained by the
presence of an NRAS mutation or a loss of NF1 function.
Considering that an activation of both the MAPK and Pi3K/
mTOR pathways occur in conjunctival melanoma, we tested
their inhibition in vitro in cell lines with a BRAFV600E or an
NRASQ61L mutation or without these mutations. Direct
inhibition of BRAF with vemurafenib in the BRAFV600E-mutated
cell line CRMM1 resulted in a moderate effect. The IC50 value
of 1.08 lM, calculated for a 72-hour treatment, is very similar to
that of previously published data on the same cell line.25
However, significant inhibition of growth was not seen at 24
hours. Interestingly, live cell imaging of the effect of
vemurafenib on BRAF-mutated cutaneous melanoma cell lines
demonstrated that at this time a significant proportion of the
cells was still dividing.38 Vemurafenib was not effective in the
NRAS-mutated cell line or the cell line with the BRAFV466E
mutation. Our data are in line with the paradoxical MAPK
activation and increased ERK phosphorylation observed in
cutaneous and conjunctival melanomas with an NRAS muta-
tion and treated with a BRAF inhibitor.25,39
Our results demonstrate that the MEK inhibitors trametinib
and selumetinib significantly decreased phosphorylation of
MEK and ERK in both the BRAFV600E and the NRAS-mutated
cell lines. However, significant growth inhibition after 72 hours
was only achieved in the BRAFV600E mutant with trametinib.
The IC50 of 10 nM obtained in our study with the BRAF-
FIGURE 4. Effect of BRAF, MAPK ,and PI3K/mTOR inhibitor treatment on MEK, ERK, and S6 protein phosphorylation of CJM cells. (A–C) Western
blots of lysates from CRMM1 and CRMM2 cells treated with increasing doses of selumetinib, trametinib, and dactolisib, respectively, for 24 hours,
showing changes in the phosphorylated forms of downstream substrates (p-ERK, p-MEK, and p-S6). Total levels of the respective proteins are shown
as control. a-Tubulin was used as a gel loading control. The figure shows the results of a representative experiment.
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mutated conjunctival melanoma cell line is similar to the values
found in primary cultures of BRAF-mutated cutaneous
melanoma, ranging from <0.1 nM to 374 nM.40 On the other
hand, the IC50 identified in the NRAS-mutated conjunctival
melanoma cell line is much higher than previously reported in
NRAS-mutated skin melanoma.40 This may be due to the fact
that NRAS can potentially activate the PIK3/mTOR pathway,
resulting in less sensitivity of the CRMM2 cell line to trametinib
inhibition. Trametinib, as a single agent, was also effective in
other NRAS-mutated cutaneous melanoma cell lines.24 In
patients with advanced cutaneous melanomas harboring BRAF
mutations, trametinib was partially effective as a single agent
but not in those with NRAS mutations.41 Although selumetinib
suppressed the growth of BRAF-mutated skin melanoma cells
lines,42 similar to what we observed in our study after 72
hours, it did not significantly improve disease-free survival in a
phase II prospective study, including patients with advanced
melanoma treated with either selumetinib or temozolomide,
regardless of the mutational BRAF or NRAS status.43
Targeting the Pi3K/mTOR pathway resulted in a significant
growth inhibition in both the BRAFV600E- and NRAS-mutated
cell lines. In our study, the single inhibition of PI3K with
pictilisib appeared to be more efficient than a dual inhibition
of PI3K and downstream mTOR with dactolisib. Pictilisib was
also the only drug with a small effect on the class 3 BRAF-
mutant cell line. In cutaneous melanoma, the efficiency of
pictilisib as a single agent has been variable: although it is
partially effective in several cell lines,44 in other cell lines
with either the BRAFV600E mutation45 or NRAS mutations,24
an effective growth inhibition could not be observed.
However, in a phase I clinical study including 60 patients
with solid tumors (among whom 5 skin melanoma patients),
the best, partial, clinical response was achieved in a patient
with a BRAFV600E-mutated metastatic cutaneous melanoma.46
Although the dual inhibition of PI3K and mTOR with
dactolisib resulted in an inactivation of S6 in both our
BRAFV600E- and NRAS-mutated cell lines, cell viability was
only significantly reduced in the BRAFV600E-mutated line. In
skin melanoma, dactolisib had a cytostatic effect in vitro and
vivo,47 but in a phase I clinical trial including several solid
tumors, no objective response could be found by using
dactolisib as a single agent.48
None of the drugs used in our study induced a significant
growth reduction in T1527A with a BRAFG466E mutation. This
mutation, occurring in the P-loop domain of BRAF, confers
impaired kinase activity49 and reduced interaction with MEK.50
It is one of the so-called class 3 BRAF mutants described
recently by Yao et al.51 with low kinase activity that are
insensitive to vemurafenib. BRAF with P-loop mutations can
bind and activate CRAF in the cytosol, leading to consecutive
MEK activation.52 This finding is in agreement with the
constitutive MAPK kinase pathway activation in T1527A, as
also described in cutaneous melanoma cell lines with
BRAFP-loop mutations.53 The lack of efficiency of MEK
inhibitors in T1527A is also consistent with MEK resistance
to MEK inhibition described in cell lines with BRAFP-loop
mutations.53 In contrast to activating BRAF mutations, class 3
BRAF mutations usually coexist in melanomas with RAS
mutations or NF1 mutations/deletion, whereas in lung and
colorectal cancers they often depend on receptor tyrosine
kinase activation for RAS activity.51 As T1527A cells were
established from a conjunctival melanoma lacking NF1
mutations and harboring wild-type NRAS, it is interesting to
note the presence of the oncogenic HRAS Q61R mutation in
T1527A, possibly through the selection of a minor clonal
subpopulation from the primary tumor already containing
HRAS Q61R mutations
In our study, the use of a single drug allowed growth
reduction, more in the BRAF-mutated and less the NRAS-
mutated cell lines. In a study by Cao et al.,25 both MEK
inhibition and AKT inhibition resulted in a synergistic effect in
the same cell lines used in our study. Similarly, in cutaneous
melanoma, synergistic inhibition of the MAPK and Pi3K
pathways has been demonstrated in cell lines with an NRAS
mutation24 and in BRAF-resistant cell lines.54 In metastatic
cutaneous melanoma cell line spheroids, the combination of
MEK and AKT inhibition prevented growth and invasion.55
However, in four phase I clinical trials assessing the use of PI3K
and MEK inhibitors in solid tumors, the overall response rate
was limited to 4.7%, with a disease control rate of 19.2%,
although a partial response was noted in a few patients with
BRAF- or NRAS-mutated melanomas.56
Over the last years, modulation of the tumor immune
microenvironment with checkpoint inhibitors has significantly
improved he survival of patients with cutaneous melano-
ma.57–61 The response to checkpoint inhibitors depends on the
local tumor immune microenvironment, that is notably the
expression of T CD8þ32 or PD-L132,62 within the tumor. In
conjunctival melanoma, the expression of PD-L1, found in 19%
(5/27) of cases, has been associated with a worse tumor-related
survival63 and might be an argument for the use of checkpoint
inhibitors in advanced conjunctival melanoma, especially
considering the relative resistance of some CJM cell lines to
MAPK or PI3K/mTOR inhibition.
In conclusion, in this study the increased activity of the
MAPK and PI3K/mTOR pathways in conjunctival melanoma
tumor progression may not rely solely on the presence of a
BRAF mutation. We further demonstrate that the responsive-
ness of the NRASQ61L and the BRAFG466E/HRASQ61R conjunc-
tival melanoma cell lines to single MAPK or PI3K inhibition is
limited. Altogether, our findings suggest that in advanced
conjunctival melanoma, the molecular genetic background of
the tumor should be determined to guide the choice of the
best therapeutic option. Further investigations into mecha-
nisms of intrinsic resistance and combination targeted thera-
pies should also be pursued.
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